- Who we areWho we are
We are a biotechnology company committed to helping address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
- What we doWhat we do
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
- Blog
Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results on February 27, 2017
Conference call details are as follows:
Date: |
| Monday, February 27, 2017 |
Time: |
| 4:30 p.m. U.S. Eastern Time (ET) |
Dial-in number: |
| (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
Passcode: |
| 61206704 |
Webcast: |
| www.novavax.com, “Investors”/ “Events” |
|
|
|
Conference call and webcast replay:
Dates: |
| Starting at 7:30 p.m. ET, February 27, 2017, until midnight March 3, 2017 |
Dial-in number: |
| (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
Passcode: |
| 61206704 |
Webcast: |
| www.novavax.com, “Investors”/ “Events”, until April 30, 2017 |
|
|
|
About
Contact:
Investor Relations
Associate Director, Investor Relations
[email protected]
240-268-2000
443-213-0506
Media
[email protected]
212-845-4271
